

BII – Protein Function Modulation for Therapeutic Interventions Publication List

REFERENCES	
1.	Tan ZW, Tee W-V, Berezovsky IN. Learning about allosteric drugs and ways to design them. <i>Journal of Molecular Biology</i> . 2022; 434:167692.
2.	Tee W-V, Tan ZW, Guarnera E, Berezovsky IN. Conservation and Diversity in Allosteric Fingerprints of Proteins for Evolutionary-inspired Engineering and Design. <i>Journal of Molecular Biology</i> . 2022; 434:167577.
3.	Tan ZW, Tee W-V, Samsudin F, Guarnera E, Bond PJ, Berezovsky IN. Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein. <i>Structure</i> . 2022;30:590-607. e4.
4.	Tee W-V, Tan ZW, Lee K, Guarnera E, Berezovsky IN. Exploring the allosteric territory of protein function. <i>The journal of physical chemistry B</i> . 2021;125:3763-80.
5.	Tee W-V, Guarnera E, Berezovsky IN. Disorder driven allosteric control of protein activity. <i>Current Research in Structural Biology</i> . 2020;2:191-203.
6.	Tan ZW, Guarnera E, Tee W-V, Berezovsky IN. AlloSigMA 2: paving the way to designing allosteric effectors and to exploring allosteric effects of mutations. <i>Nucleic acids research</i> . 2020;48:W116-W24.
7.	Ghode A, Gross LZ, Tee W-V, Guarnera E, Berezovsky IN, Biondi RM, et al. Synergistic allostery in multiligand-protein interactions. <i>Biophysical journal</i> . 2020;119:1833-48.
8.	Tee W-V, Guarnera E, Berezovsky IN. On the Allosteric Effect of nsSNPs and the Emerging Importance of Allosteric Polymorphism. <i>Journal of Molecular Biology</i> . 2019.
9.	Tee W-V, Guarnera E, Berezovsky IN. Reversing allosteric communication: From detecting allosteric sites to inducing and tuning targeted allosteric response. <i>PLoS computational biology</i> . 2018;14:e1006228.
10.	Tan ZW, Tee W-V, Guarnera E, Booth I, Berezovsky IN. AlloMAPS: allosteric mutation analysis and polymorphism of signaling database. <i>Nucleic acids research</i> . 2018;47:D265-D70.
11.	Kabir MZ, Tee W-V, Mohamad SB, Alias Z, Tayyab S. Comprehensive insight into the binding of sunitinib, a multi-targeted anticancer drug to human serum albumin. <i>Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</i> . 2017;181:254-63.
12.	Tee W-V, Ripen AM, Mohamad SB. The conformational dynamics of H2-H3n and S2-H6 in gating ligand entry into the buried binding cavity of vitamin D receptor. <i>Scientific reports</i> . 2016;6:1-8.
13.	Tayyab S, Izzudin MM, Kabir MZ, Feroz SR, Tee W-V, Mohamad SB, et al. Binding of an anticancer drug, axitinib to human serum albumin: Fluorescence quenching and molecular docking study. <i>Journal of Photochemistry and Photobiology B: Biology</i> . 2016;162:386-94.
14.	Kabir MZ, Tee W-V, Mohamad SB, Alias Z, Tayyab S. Interaction of an anticancer drug, gefitinib with human serum albumin: insights from fluorescence spectroscopy and computational modeling analysis. <i>RSC advances</i> . 2016;6:91756-67.